FBC advises Monsanto, in an investment in Evogene, a publicly traded Israeli company that develops genetic engineering technology, in its acquisition of Rosetta Green, a public Israeli company, and the Beelogics group of companies.
FBC advises Monsanto in investment in Evogene and acquisitions of Rosetta Green and the Beelogics group of companies
By Hagar Keren-Hackim & Amit Dat & Itiel Ben-Haim & Ronald Lehmann & Raz Tepper & Ron Sitton | Feb 2013 | Transaction
Search by
- Arbitration & Mediation
- Aviation & Maritime
- Banking & Finance
- Blockchain and Cryptocurrency
- Capital Markets
- Class Actions & Derivative Suits
- Commercial
- Competition & Antitrust
- Cybersecurity, IT & Data Protection
- East Asia Desk
- Environmental
- Family & Inheritance Law
- FinTech
- French Desk
- Global Talent Mobility & Relocation
- Hi-Tech, Technology & Venture Capital
- Hotels & Tourism
- Insolvency & Restructuring
- Intellectual Property
- Investment Funds
- Labor & Employment
- Life Sciences & Healthcare
- Liquidation & Receivership
- Litigation
- Mergers & Acquisitions
- Philanthropy
- Planning & Zoning
- Private Asset Management
- Private Equity
- Project Finance & Energy
- Real Estate
- Regulatory
- Sports Law
- Tax
- Tax - Municipal Tax
- Tech Litigation
- Telecom & Media
- White Collar